Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iFCG in First-Line CLL with Mutated IGHV and Non-Del(17p)
NCT02629809Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2016
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Remission/Complete Remission with Incomplete Marrow Recovery and Bone Marrow Minimal Residual Disease-Negative Status at 84 days. Started Mar 2016; status: active, not recruiting.
02
Drugs
ibrutinibfludarabinecyclophosphamideobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02629809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629809.